Clinical Trial Update: PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a PD-1 antibody plus XELOX in first-line gastric or gastroesophageal junction adenocarcinoma with elevated AFP; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric or Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: China Medical University, China | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, AFP | Phase 2 | Status: UNKNOWN